|
Q3 FY2026
As of Dec 31, 2025
|
Q2 FY2026
As of Sep 30, 2025
|
Q1 FY2026
As of Jun 30, 2025
|
Q4 FY2025
As of Mar 31, 2025
|
Q3 FY2025
As of Dec 31, 2024
|
Q2 FY2025
As of Sep 30, 2024
|
Q1 FY2025
As of Jun 30, 2024
|
Q4 FY2024
As of Mar 31, 2024
|
Q3 FY2024
As of Dec 31, 2023
|
Q2 FY2024
As of Sep 30, 2023
|
Q1 FY2024
As of Jun 30, 2023
|
Q4 FY2023
As of Mar 31, 2023
|
Q3 FY2023
As of Dec 31, 2022
|
Q2 FY2023
As of Sep 30, 2022
|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
Q2 FY2022
As of Sep 30, 2021
|
Q1 FY2022
As of Jun 30, 2021
|
Q4 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Bank indebtedness | ||||||||||||||||||||
| Bank indebtedness | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Convertible promissory notes, net of debt discount | ||||||||||||||||||||
| Advances from related party | ||||||||||||||||||||
| Convertible note outstanding balance | ||||||||||||||||||||
| Promissory note | ||||||||||||||||||||
| Promissory note - related party | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Asset retirement obligations | ||||||||||||||||||||
| Total Non Current Liabilities | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| SHAREHOLDERS' DEFICIT | ||||||||||||||||||||
| Common stock: 300,000,000 authorized; $0.001 par value 22,996,680 shares issued and outstanding | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| TOTAL SHAREHOLDERS' DEFICIT | ||||||||||||||||||||
| TOTAL LIABILITIES & SHAREHOLDERS' DEFICIT |
Loading...
